Treasury
3-MO 4.21% -1bp 6-MO 4.28% -2bp 1-YR 4.46% -1bp 2-YR 4.79% -5bp 3-YR 4.88% -9bp 5-YR 5.03% -3bp 7-YR 5.15% -4bp 10-YR 5.27% -4bp 20-YR 5.68% -2bp 30-YR 5.64% -2bp 3-MO 4.21% -1bp 6-MO 4.28% -2bp 1-YR 4.46% -1bp 2-YR 4.79% -5bp 3-YR 4.88% -9bp 5-YR 5.03% -3bp 7-YR 5.15% -4bp 10-YR 5.27% -4bp 20-YR 5.68% -2bp 30-YR 5.64% -2bp 3-MO 4.21% -1bp 6-MO 4.28% -2bp 1-YR 4.46% -1bp 2-YR 4.79% -5bp 3-YR 4.88% -9bp 5-YR 5.03% -3bp 7-YR 5.15% -4bp 10-YR 5.27% -4bp 20-YR 5.68% -2bp 30-YR 5.64% -2bp 3-MO 4.21% -1bp 6-MO 4.28% -2bp 1-YR 4.46% -1bp 2-YR 4.79% -5bp 3-YR 4.88% -9bp 5-YR 5.03% -3bp 7-YR 5.15% -4bp 10-YR 5.27% -4bp 20-YR 5.68% -2bp 30-YR 5.64% -2bp 3-MO 4.21% -1bp 6-MO 4.28% -2bp 1-YR 4.46% -1bp 2-YR 4.79% -5bp 3-YR 4.88% -9bp 5-YR 5.03% -3bp 7-YR 5.15% -4bp 10-YR 5.27% -4bp 20-YR 5.68% -2bp 30-YR 5.64% -2bp 3-MO 4.21% -1bp 6-MO 4.28% -2bp 1-YR 4.46% -1bp 2-YR 4.79% -5bp 3-YR 4.88% -9bp 5-YR 5.03% -3bp 7-YR 5.15% -4bp 10-YR 5.27% -4bp 20-YR 5.68% -2bp 30-YR 5.64% -2bp
US Treasury par yield curve · Oct 6 · Source: U.S. Treasury
Tuesday, October 6, 2026
U.S. Edition
MONEY & WORLD
Subscribe
Biotechnology

Caribou stops two cell therapy programs and starts a substantial workforce reduction

Money & World
The Editorial Team ·
Laboratory test tubes receiving blue liquid during an experiment Stock photo
Stock photo. Not the actual scene. Photo: Carlos Garcia / Pexels

The filing ends both programs. Caribou Biosciences will discontinue development of vispa-cel and CB-011, make a substantial workforce reduction and explore strategic alternatives, according to a Form 8-K filed Tuesday.

Most departures are expected this quarter.

Caribou estimates restructuring expenses of $15m to $19m. That includes about $10m to $11m for severance, continued health coverage and related costs, plus $5m to $8m to wind down two phase 1 trials.

The company reported $113.8m of cash, cash equivalents and marketable securities as of June 30.

The board is considering a merger, acquisition, business combination or another transaction. It has set no timeline, and no deal has been announced.

The document: Caribou Biosciences Form 8-K, restructuring and strategic review, October 6, 2026, accession 0001193125-26-415559.

More on Finance